Study:
Phase II Study of Neoadjuvant Doxorubicin and Ifosfamide, Radiotherapy, and Surgical Resection in Patients With Primary or Recurrent Retroperitoneal Sarcoma
Rationale:
Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
Combining chemotherapy, radiation therapy, and surgery may kill more tumor cells.
Purpose:
Phase II trial to study the effectiveness of combination chemotherapy, radiation
therapy, and surgery in treating patients who have primary or recurrent sarcoma.
Study Status: Withdrawn
Recruiting:
n/a
| Condition |
Intervention |
Phase |
Stage III Adult Soft Tissue Sarcoma
Recurrent Adult Soft Tissue Sarcoma
Stage IVA Adult Soft Tissue Sarcoma
Stage IIB Adult Soft Tissue Sarcoma
Stage IIC Adult Soft Tissue Sarcoma |
Drug: doxorubicin
Drug: filgrastim
Drug: ifosfamide
Procedure: biological response modifier therapy
Procedure: brachytherapy
Procedure: chemotherapy
Procedure: colony-stimulating factor therapy
Procedure: conventional surgery
Procedure: cytokine therapy
Procedure: intraoperative radiotherapy
Procedure: radiation therapy
Procedure: surgery |
Phase 2 |
Verified by
Radiation Therapy Oncology Group
December, 2006
Sponsored by: Radiation Therapy Oncology Group
Information provided by: National Cancer Institute (NCI)
ClinicalTrials.gov identifier: NCT00017160
Study Type: Interventional
Study Design: Treatment
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio 44195
United States
Peter W. T. Pisters, MD., Study Chair